For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| GMI-1070 | GMI-1070 administered IV at 20 mg/kg loading dose, followed by a single dose of 10 mg/kg in the evening | None | None | 0 | 15 | 9 | 15 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Headache | None | Nervous system disorders | None | View |
| Anemia | None | Blood and lymphatic system disorders | None | View |
| Leukocytosis | None | Blood and lymphatic system disorders | None | View |
| sickle cell anemia with crisis | None | Congenital, familial and genetic disorders | None | View |
| vomiting | None | Gastrointestinal disorders | None | View |
| infusion site pain | None | General disorders | None | View |
| arthralgia | None | Musculoskeletal and connective tissue disorders | None | View |
| cough | None | Respiratory, thoracic and mediastinal disorders | None | View |
| oropharyngeal pain | None | Respiratory, thoracic and mediastinal disorders | None | View |
| pruritus | None | Skin and subcutaneous tissue disorders | None | View |
| hypokalemia | None | Metabolism and nutrition disorders | None | View |